Gut - McMaster Experts

publication venue for

The national prevalence of disorders of gut-brain interaction in the United Kingdom compared to their worldwide prevalence 2023
IDDF2021-ABS-0025 Discriminating endoscopic features of sessile serrated lesions: a systematic review and meta-analysis 2021
O61 Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis 2021
Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis 2020
IDDF2019-ABS-0136 Sofosbuvir/velpatasvir for 12 weeks is safe and effective in patients undergoing dialysis 2019
PWE-076 Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis 2019
PTH-140 Virtual reality simulation training in gastrointestinal endoscopy: a cochrane systematic review 2018
PWE-124 Daily aspirin 300mg: how much do patients take? drug accountability for the first 5 years of the aspect study 2017
AN INVESTIGATION OF GASTROINTESTINAL SYMPTOMS, PSYCHOLOGICAL WELL-BEING AND COGNITIVE PERFORMANCE IN INFORMAL DEMENTIA CAREGIVERS 2017
PTU-149 Barrett’s Oesophagus Patients Attending Hospital: Baseline Clinical, Patient History and Quality of Life Data from Boss and Aspect 2016
OC-002 Selective Alpha V Integrin Deletion Identifies a Core, Targetable Molecular Pathway that Regulates Fibrosis Across Solid Organs 2013
Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report 2012
Efficacy of antidepressants in irritable bowel syndrome: an updated systematic review and meta-analysis controlling for depression 2011
Rome III criteria for functional gastrointestinal disorders: too much overlap to be useful? 2011
PWE-078 Intragastric ph holding time of pH <4 predicts low erosive esophagitis healing rate 2010
PWE-079 Use of antisecretory medication after antireflux surgery for patients with gastro-oesophageal reflux disease: a systematic review of non-randomised studies 2010
A cross-sectional survey to assess the usefulness of the rome III dyspepsia symptom subgroups in a large community sample 2007
Esomeprazole for treatment of unexplained chest pain in primary care: A prospective, randomised, double-blind, placebo-controlled multicentre study 2007
Poor quality of life predicts the new onset of irritable bowel syndrome. A longitudinal 10-year follow-up study 2007
Who consults with irritable bowel syndrome? A longitudinal 10-year follow-up study 2007
A 10 year natural history of gastrooesophageal reflux disease 2006
A cross sectional survey of the relationship between gastrooesophageal reflux disease and chronic cough 2006
Audit: Is the age limit of 55 years (NICE 2004) for endoscoping dyspeptic patients without alarm symptoms safe? 2006
Effect of sibling number and birth order on Helicobacter pylori prevalence: A cross sectional survey 2006
Helicobacter pylori infection confers an increase in 10 year mortality from all causes: Data from a community screening programme 2006
Use of soluble transferrin receptors is a valuable, resource-sparing tool in iron deficiency diagnosis 2006
Who consults with dyspepsia? A 10 year cross sectional survey 2006
Esomeprazole and pantoprazole: A comparison for maintenance treatment of healed erosive oesophagitis 2005
Ten year follow-up of a community screening and treatment programme for H pylori 2005
A retrospective case control study to determine the risk of Barrett's oesophagus according to ethnic origin 2004
Mortality risk factors and comorbidity in patients with Barrett's metaplasia 2004
A systematic review and economic analysis of the cost-effectiveness of proton pump inhibitor therapy in non-ulcer dyspepsia 2003
A systematic review of helicobacter pylori eradication therapy in duodenal and gastric ulcer healing and maintenance 2003
Audit of the 2 week rule (TWR) for suspected upper gastrointestinal (UGI) cancer and the pathways to diagnosis 2003
Cost effectiveness of h pylori "test and treat" versus PPI for uninvestigated dyspepsia: Modelling and meta-analysis in the design of the MRC-CUBE trial 2003
How best to assess symptomatic outcomes of therapy in gastro-oesophageal reflux disease trials: A systematic review 2003
Survey of current clinical practice in the diagnosis, management and surveillance of Barrett's metaplasia: A UK national survey 2003
The value of drugs to treat upper gastrointestinal symptoms: What are patients willing to pay? 2003
Clinical and economic consequences of dyspepsia in the community 2002
Helicobacter pylori test and treat strategy for young dyspeptic patients: new data 2002
A comparison of systematic reviews of Helicobacter pylori eradication for non-ulcer dyspepsia 2002
The effect of reduced quality of life on the subsequent development of dyspepsia and irritable bowel syndrome: A prospective cohort study 2002
The influence of antibiotics on irritable bowel syndrome: A randomised controlled trial 2002
A multi-laboratory comparison of proficiency in testing susceptibility of Helicobacter pylori, and correlation between agar dilution and E test methods 2001
Patient preference and willingness to pay for helicobacter stool antigen test compared to breath test 2001
The role of Helicobacter pylori (H.p.) infection in predicting endoscopic abnormalities in 1040 patients with uninvestigated dyspepsia (UD). The CADET-PE study 2001
The appropriateness of measuring the benefit of dyspepsia management in terms of quality adjusted life years 2001
Bismuth-based Helicobacter pylori (Hp) therapy by a single capsule [(Bismuth subcitrate (B) plus metronidazole (M) plus tetracycline (T)] plus omeprazole (O) vs O plus amoxicillin (A) plus clarithromycin (C): An interim analysis. 2000
A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcer dyspepsia (NUD) 2000
A systematic review of pharmacological therapies in non-ulcer dyspepsia. 2000
Establishing patient preferences for one-stop gastrointestinal clinics using conjoint analysis 2000
How much are dyspeptic patients willing to pay for endoscopy compared with H pylori "test and treat" service? 2000
The prevalence of Helicobacter pylori in bleeding peptic ulcer disease 1999
Accuracy of a new antigen based stool test for Helicobacter pylori (HP) in 117 endoscoped patients before and after treatment, European multicentre study. 1999
An evidence-based appraisal of reflux disease management --- the Genval Workshop Report 1999
Changing patterns of H-pylori gastritis in long-standing acid suppression 1999
Does eradication of Helicobacter pylori influence the recurrence of symptoms in patients with symptomatic gastro-oesophageal reflux disease? A randomised double blind study. 1999
H pylori screening and treatment reduces dyspepsia in the community. 1999
Incidence of Crohn's disease (CD) and ulcerative colitis (UC) in three regional centres in England. 1999
Low mortality rate in Crohn's disease (CD) and ulcerative colitis (UC) in three regional centres in England. 1999
Population H pylori screening and treatment reduces dyspepsia costs. 1999
Second-line eradication for H-pylori after failure of therapy with proton pump inhibitor (PPI), clarithromycin and metronidazole: Results of a case series. 1999
Seven days of omeprazole and clarithromycin with either amoxicillin or metronidazole for H-pylori eradication - Results of a single-blinded randomised trial in the community. 1999
The cost-effectiveness of an H-Pylori screen and treat strategy in dyspeptic patients presenting in primary care. 1999
The prevalence and severity of irritable bowel syndrome (IBS) in the community in those with and without a primary care diagnosis. 1999
Screening and treating for H-pylori - Is it cost-effective in clinical practice? 1998
Any role left for invasive tests? Histology in clinical practice 1998
Can pets act as a vector for Helicobacter pylori transmission? 1998
Sumatriptan, a 5-HT1 agonist, increases gastrooesophageal reflux. 1998
The effectiveness and side effects of a community Helicobacter pylori eradication programme. 1998
The influence of dyspepsia, Helicobacter pylori status and irritable bowel syndrome on quality of life in the community. 1998
What proportion of dyspepsia in the general population is attributable to Helicobacter pylori? 1998
A novel approach to assess brain processing of esophageal sensation using cognitive evoked P300-potentials 1997
Amelioration of experimental colitis by interleukin-10 gene transfer 1997
Effectiveness of omeprazole, clarithromycin and tinidazole against Helicobacter pylori in a community screening and eradication programme 1997
Evidence for intrafamilial transmission of Helicobacter pylori infection in adults 1997
Helicobacter pylori and the risk of stroke 1997
Influence of Helicobacter pylori status on adult height 1997
Isolation of H-pylori from gastric juice 1997
Optimal electrical stimulus for esophageal potentials: Transmural or intraesophageal? 1997
Study of gastric emptying in patients with non-ulcer dyspepsia evaluated by the paracetamol absorption technique: Preliminary results 1997
The magnitude of autonomic responses to esophageal electrical stimulation is modulated by cortical perception 1997
Validation of a new one-step near patient Helicobacter pylori test 1997
Accuracy of the Helisal rapid blood kit and its use in pre-endoscopic screening 1997
Evidence for intrafamilial transmission of Helicobacter pylori infection in adults 1997
Isolation of H-pylori from gastric juice 1997
Validation of a new one-step near patient Helicobacter pylori test 1997
Adult social class as an independent risk factor for Helicobacter pylori. 1997
Alosetron slows colonic transit in patients with irritable bowel syndrome (IBS) 1997
Dyspepsia and irritable bowel syndrome in the community. 1997
Further evidence that sumatriptan induced chest pain is oesophageal in origin: Effect on oesophageal visceral sensation. 1997
Influence of siblings on risk of Helicobacter pylori infection. 1997
Sumatriptan at a therapeutic dose alters oesophageal motility. 1997
The optimum 5 day therapy against Helicobacter pylori. 1997
GASTRIC-ACID SUPPRESSION AND HEALING OF GASTROESOPHAGEAL REFLUX DISEASE - CAN PHYSIOLOGICAL-STUDIES PREDICT RESPONSE 1992
HEALTHY-MALES RECEIVING H-2-RECEPTOR ANTAGONIST INFUSION AND PARENTERAL OR ENTERAL FEEDING SHOW NO DIFFERENCES IN PLASMA GASTRIN-LEVELS 1992
TRANSRECTAL ULTRASOUND (TRUS) SURVEILLANCE OF ENDOCAVITARY RADIATION (RT 50) TREATED RECTAL-CANCER 1992
ERADICATION OF HELICOBACTER-PYLORI - METAANALYSIS TO DETERMINE OPTIMAL THERAPY 1991
GASTROJET INFUSION OF RANITIDINE AND INTRADUODENAL NUTRITION - A MORE RATIONAL PROPHYLAXIS FOR STRESS ULCERATION 1991
DUODENAL ULCERATION DURING MAINTENANCE RANITIDINE THERAPY - SILENT AND DEADLY 1991
MISOPROSTOL DOES NOT PREVENT THE GASTRODUODENAL MUCOSAL EFFECTS OF THE NONSTEROIDAL ANTIINFLAMMATORY DRUG, DICLOFENAC 1991
PERSISTENT GASTRITIS AFTER RANITIDINE OR ANTACID THERAPY PREDICTS RELAPSE OF DUODENAL ULCERATION 1991
HISTAMINE-RECEPTORS IN CANINE GASTRIC AND COLONIC MUSCULARIS MUCOSAE 1990
PALLIATION OF ESOPHAGEAL-CARCINOMA WITH YAG LASER AND ENDOLUMINAL CESIUM RADIATION 1990
24 HOUR PATTERN OF ESOPHAGEAL MOTILITY 1989
COMPUTER ANALYZED AMBULATORY MANOMETRY OF ESOPHAGEAL MOTILITY 1989
EVENTUAL DIAGNOSES AND OUTCOME IN PATIENTS DISCHARGED FROM CORONARY-CARE WITH UNDIAGNOSED CHEST PAIN 1989
FULL DOSE H2 RECEPTOR ANTAGONIST PROPHYLAXIS DOES NOT PREVENT RELAPSE OF REFLUX ESOPHAGITIS 1989
CHRONIC ENTEROGASTRIC REFLUX (EGR) INCREASES THE GASTROTOXICITY OF AN ACUTE BILE-ACID CHALLENGE IN THE RAT 1988
IS CONTINUOUS AMBULATORY MONITORING OF DUODENOGASTRIC REFLUX FEASIBLE - INVITRO ASSESSMENT OF AN ENZYMATIC AMPEROMETRIC BILE-ACID ELECTRODE 1987
ARE BILE-ACIDS GASTROTOXIC IN DUODENOGASTRIC REFLUX - DOSE-RESPONSE AND STRUCTURE ACTIVITY STUDIES USING AN EXVIVO RAT GASTRIC CHAMBER MODEL 1986
PERMEABILITY OF INFLAMED JEJUNUM TO CR-51 EDTA IN THE INVIVO RAT 1986
COLONIC PERMEABILITY TO CR-51-EDTA IN INFLAMMATORY BOWEL-DISEASE 1985
HEMOCCULT TESTING IN GENERAL-PRACTICE FOR EARLY DIAGNOSIS OF COLORECTAL-CANCER 1984
INTESTINAL MUCOSAL MAST-CELL AND ITS RESPONSE TO GUT HORMONES 1983
PULMONARY-FUNCTION ABNORMALITIES IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE 1982
PROGNOSIS OF COLONIC CARCINOMAS DIAGNOSED BY COLONOSCOPY 1980
COLONOSCOPY FOR UNEXPLAINED RECTAL BLEEDING 1976
Wheat proteins as triggers of central nervous system inflammation. 73:5-6. 2024
Obesity promotes a leaky gut, inflammation and pre-diabetes by lowering gut microbiota that metabolise ethanolamine. 72:1809-1811. 2023
Changes in signalling from faecal neuroactive metabolites following dietary modulation of IBS pain. 72:1678-1691. 2023
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis. 72:1462-1471. 2023
Correspondence on “PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system” by Guiet al. 72:805-807. 2023
Understanding neuroimmune interactions in disorders of gut–brain interaction: from functional to immune-mediated disorders. 72:787-798. 2023
Human gut microbiota after bariatric surgery alters intestinal morphology and glucose absorption in mice independently of obesity. 72:460-471. 2023
Consensus-based development of a causal attribution system for post-ERCP adverse events. 71:1963-1966. 2022
Efficacy ofHelicobacter pylorieradication therapy for functional dyspepsia: updated systematic review and meta-analysis. 71:1967-1975. 2022
Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. 71:1773-1780. 2022
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report. 71:1724-1762. 2022
Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD). 71:1078-1087. 2022
Gluten-induced RNA methylation changes regulate intestinal inflammation via allele-specific XPO1 translation in epithelial cells. 71:68-76. 2022
Uniting the global gastroenterology community to meet the challenge of climate change and non-recyclable waste. 70:2025-2029. 2021
Helicobacter pylorieradication therapy to prevent gastric cancer: systematic review and meta-analysis. 69:2113-2121. 2020
USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation. 69:1322-1334. 2020
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. 69:74-82. 2020
Proton pump inhibitors and gastric cancer: association is not causation. 68:1529.2-1530. 2019
Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. 67:430-440. 2018
Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. 66:1739-1747. 2017
FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. 66:1241-1251. 2017
Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. 66:411-420. 2017
Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report. 66:6-30. 2017
Non-coeliac gluten sensitivity: are we closer to separating the wheat from the chaff?. 65:1921-1922. 2016
The stomach in health and disease. 64:1650-1668. 2015
Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. 64:1049-1057. 2015
The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. 64:406-417. 2015
Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. 63:703.1-703. 2014
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. 63:7-42. 2014
Intestinal microbiota in functional bowel disorders: a Rome foundation report. 62:159-176. 2013
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant inNCF2that results in reduced binding to RAC2. 61:1028-1035. 2012
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). 61:535-542. 2012
The microbiota-gut-brain axis: learning from intestinal bacteria?. 60:288-289. 2011
Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. 59:605-611. 2010
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. 59:325-332. 2010
Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. 58:1490-1497. 2009
Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. 58:1473-1479. 2009
Alarm features of colorectal cancer Reply. 58:1026-1027. 2009
Authors' reply. 58:1026-1027. 2009
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. 58:367-378. 2009
Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. 57:1545-1553. 2008
Re-analysis of application of haemoclips for non-variceal upper gastrointestinal bleeding data.. 57:1023-1024. 2008
Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. 57:475-481. 2008
Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. 57:50-58. 2008
Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. 56:1522-1528. 2007
CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection. 56:949-957. 2007
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. 56:772-781. 2007
Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. 56:321-327. 2007
Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse. 56:358-364. 2007
Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. 55:1553-1560. 2006
The putative role of endogenous and exogenous opiates in inflammatory bowel disease. 55:756-757. 2006
Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1. 55:662-670. 2006
Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. 55:182-190. 2006
East meets West: infection, nerves, and mast cells in the irritable bowel syndrome. 53:1068-1069. 2004
Effect of Th1 cytokines on acid secretion in pharmacologically characterised mouse gastric glands. 53:1075-1081. 2004
Sexual and physical abuse are not associated with rectal hypersensitivity in patients with irritable bowel syndrome. 53:838-842. 2004
A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials. 53:iv58-iv65. 2004
Bringing science to the art of diagnosis. 53:627-628. 2004
New approaches to enhance the accuracy of the diagnosis of reflux disease. 53:iv55-iv57. 2004
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. 53:iv1-iv24. 2004
Putative therapeutic targets in the treatment of visceral hyperalgesia. 53:19ii-21. 2004
JournalScan. 52:1653-1654. 2003
Neutral endopeptidase (EC 3.4.24.11) downregulates the onset of intestinal inflammation in the nematode infected mouse. 52:1457-1464. 2003
JournalScan. 52:1382-1382. 2003
JournalScan. 52:1219-1219. 2003
Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. 52:966-970. 2003
Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. 52:523-526. 2003
Bile reflux gastritis and intestinal metaplasia at the cardia. 51:351-355. 2002
Helping patients to help themselves: the future for management of ulcerative colitis?. 51:309-310. 2002
Defining the roles of perforin, Fas/FasL, and tumour necrosis factor in T cell induced mucosal damage in the mouse intestine. 51:155-163. 2002
Intestinal inflammation and activation of sensory nerve pathways: a functional and morphological study in the nematode infected rat. 49:822-827. 2001
The putative role of inflammation in the irritable bowel syndrome. 49:743-745. 2001
Cardiac autonomic function and oesophageal acid sensitivity in patients with non-cardiac chest pain. 49:706-712. 2001
Counting the cost of proton pump inhibitors. 49:462-463. 2001
Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro-oesophageal reflux?. 49:359-363. 2001
Dyspepsia: The Clinical Consequences.. 49:314.1-314. 2001
Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. 48:630-636. 2001
Memory in the enteric nervous system. 47:60iv-62. 2000
Interleukin 10 gene transfer prevents experimental colitis in rats. 46:344-349. 2000
Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. 45:295-300. 1999
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. 45:172-180. 1999
Treatment after failure: the problem of "non-responders". 45:i40-i44. 1999
Omeprazole:Helicobacter pylori makes thee greater yet. 44:448-449. 1999
The role of psychological and biological factors in postinfective gut dysfunction. 44:400-406. 1999
Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group.. 41 Suppl 2:S1-S9. 1997
Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.. 41:33-36. 1997
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.. 40:775-781. 1997
Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.. 37:743-748. 1995
Relation of acupuncture and vagal gastric acid secretion.. 36:800-801. 1995
Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole.. 36:539-543. 1995
Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds.. 35:455-460. 1994
Nocturnal oesophageal motor activity is dependent on sleep stage.. 34:1653-1659. 1993
Prospective multicentre study of risk factors associated with delayed healing of recurrent duodenal ulcers (RUDER). RUDER Study Group.. 34:1319-1326. 1993
Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study.. 34:1025-1031. 1993
Relation of pyloric motility to pyloric opening and closure in healthy subjects.. 33:466-471. 1992
Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.. 33:118-124. 1992
Effect of hydrochloric acid and prostaglandins on pepsinogen synthesis and secretion in canine gastric chief cell monolayer cultures.. 30:774-781. 1989
Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 94482, a new H2 receptor antagonist which has a profound effect on daytime acidity.. 30:594-599. 1989
Prospective comparison of double contrast barium enema plus flexible sigmoidoscopy v colonoscopy in rectal bleeding: barium enema v colonoscopy in rectal bleeding.. 29:1188-1193. 1988
Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist.. 29:890-893. 1988
Changes in intestinal permeability and epithelial differentiation during inflammation in the rat.. 29:57-61. 1988
Electrical correlate of circumferential contractions in human colonic circular muscle.. 29:10-16. 1988
Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs.. 28:1120-1127. 1987
Relationship between gastric secretion and infection.. 28:96-107. 1987
Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.. 27:1058-1061. 1986
Gastric secretion in patients with typhoid.. 26:1387-1388. 1985
Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders.. 25:1211-1216. 1984
Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.. 24:904-908. 1983
Towards safer colonoscopy.. 24:371-375. 1983
Oxmetidine: clinical pharmacological studies with a new H2-receptor antagonist.. 23:157-163. 1982
Comparison of twice-daily ranitidine with standard cimetidine treatment of duodenal ulcer.. 22:319-322. 1981
Comparison of the effects of ranitidine, cimetidine and placebo on the 24 hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer.. 22:49-54. 1981
SK&F 93479 is a long-acting inhibitor of gastric acid secretion in man. 22. 1981
24-hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer during oral administration of cimetidine and atropine.. 18:85-90. 1977
Is intrinsic factor really affected by cimetidine?. 18. 1977
24 Hour intragastric acidity and nocturnal acid secretion in patients with duodenal ulcer during oral administration of cimetidine and atropine. 17:831. 1976
The effect of intravenous prostaglandin F2 alpha and E2 on the motility of the sigmoid colon.. 16:47-49. 1975
Simple atrophic gastritis and gastric carcinoma. 12:906-911. 1971
Clinical trial of deglydyrrhizinized liquorice in gastric ulcer.. 10:299-302. 1969
Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects.. 6:591-594. 1965
Iron loading and the liver: the effect on regeneration after partial hepatectomy. 5:374-378. 1964
The absorption of tritium-labelled pyridoxine HCl in control subjects and in patients with intestinal malabsorption. 5:241-247. 1964

Gut Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)